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                                                ABSTRACT 
Title: Retrospective Analysis of Outcomes in the Programme of Fast-tracking 
of Antiretroviral Therapy for Patients Admitted to a Palliative Care Centre after 
Diagnosis of Opportunistic Infections. 
Background : Although national guidelines in South Africa recommend starting 
antiretroviral therapy (ART) mainly to outpatients with WHO stage four disease and 
/or CD4 count of 200 cells/uL, immediate ART  initiation after opportunistic infection 
(OI) treatment in the inpatient wards at several international sites has been shown to 
reduce the adverse outcomes of AIDS progression and death. This study describes 
a retrospective analysis of the effect of immediate initiation of ART after acute OI 
including tuberculosis in ART-naive patients hospitalised in Durban, South Africa. 
Methods: Eligible patients who were admitted with acute OI were initiated on 
immediate ART in a palliative care centre. We conducted a retrospective quantitative 
analysis of patient information at admission and 24 weeks. The primary and 
secondary endpoints were 24-week mortality and virological outcome respectively.   
A convenience sampling was used covering a nine month period. 
Results: 93 patients were enrolled (50% women, median age 37 years).  The 
median CD4 cell count in this group with advanced AIDS was 21 cells/uL.  OIs 
included pulmonary tuberculosis, 17%, tuberculosis meningitis, 11% and other extra 
pulmonary tuberculosis, 37%; cryptococcal meningitis, 13% and Pneumocystis 
pneumonia, 11%. The median number of days to ART after initial treatment for OI 
















Immune Reconstitution Inflammatory Syndrome (IRIS) event; IRIS occurred in one of 
12 patients with baseline cryptococcal meningitis and there was one IRIS-associated 
death.  Among patients who remained in care, at 24 weeks 92% achieved virological 
suppression and the median improvement in CD4 cell count was 90 cells/uL with 
two-thirds achieving an improvement to above 100 cells/uL. The overall mortality in 
this clinically advanced patient group was 20% (95% CI: 13 -29%) and loss to follow-
up was 6%.  
Conclusion: Current South African policies of discharging patients after hospital 
admission for management of OIs for follow up and initiation of antiretroviral 
treatment at ARV clinics result in poor patient outcomes as described by reports from 
South Africa. In contrast, this study demonstrates the feasibility and effectiveness, 
under routine programme conditions, of a rapid, supervised inpatient ART initiation. 
Further research is needed to reduce the known high rate of early mortality among 
patients with advanced HIV disease.  


















                                  TABLE OF CONTENTS        1 
DECLARATION ..................................................................................................................... 2 
ACKNOWLEDGEMENTS..................................................................................................... 3 
ABSTRACT ............................................................................................................................. 4 
TABLES OF CONTENTS ...................................................................................................... 6 
TABLE OF TABLES .............................................................................................................. 8 
ACRONYMS AND ABBREVIATIONS ............................................................................... 9 
INTRODUCTION ................................................................................................................ 10 
AIMS AND OBJECTIVES OF RESEARCH ...................................................................... 20 
LITERATURE REVIEW ..................................................................................................... 21 
METHODOLOGY ................................................................................................................ 34 
RESULTS .............................................................................................................................. 39 
DISCUSSION ........................................................................................................................ 49 

































                                  TABLE OF TABLES  
Table 1: Baseline characteristics of first 100 patients at the time of OI when admitted 
to the acute care wards from November 2006 to May 2007.                                  p38 
 
 Table 2: Initial 24-week outcomes after immediate ART commenced at Siyaphila 
from November 2006 to May 2007                                                                         p41 
 Table 3: Univariate Analysis of Factors Associated with 24-Week Mortality after 
Acute OI and ART initiation in the first 100 patients at Siyaphila from November 



















                                        ACRONYMS AND ABBREVIATIONS 
AIDS –Auto Immune Deficiency Syndrome 
ART –Antiretroviral therapy 
DHHS-Department of Health and Human Sciences 
HIV –Human Immunodeficiency Virus 
OI –Opportunistic Infection 
PLWHA-People Living With HIV/AIDS 
UNAIDS –United Nations AIDS 
















                                          INTRODUCTION 
 Current South African policies of discharging patients after hospital management of 
OIs for follow up and initiation of antiretroviral treatment at ART clinics result in poor 
patient outcomes as described by reports from South Africa .1 The proposed study 
seeks to describe the feasibility and effectiveness, under routine programme 
conditions, of a rapid, supervised inpatient ART initiation.  
Guidelines on when to start ART in resource poor settings 
At the  International AIDS Society (IAS) meeting in Cape Town in July 2009, the 
president of the South African  HIV Clinicians Society, Dr .F. Venter made a 
comprehensive assessment of the evidence used in various settings to decide about 
the most appropriate CD4 count at which to initiate ART.2  His arguments are 
summarised in this paragraph.  In South Africa, the threshold in the public health 
system remains 200cells/uL, based on the Department of Health guidelines 
published in 2004.  In the private sector, medical schemes are generally using a 
threshold of 350cells/uL, based on the Southern African HIV Clinicians Society 
Guidelines.  Other Sub- Saharan countries generally use a 200 threshold as well. 
Meanwhile, Europe and North America also initiate at first CD4 count below 
350cells/uL.3 
 The 350 cells/uL threshold is supported with evidence from several studies: The 
When to Start Consortium, in an analysis of 15 cohorts studies, found a greater than 
two times hazard ratio for progression to AIDS or death in people with CD4 counts 
















300cells/ul.There was also a significant difference in progression between the CD4 
count strata 151- 250cells/uL and 251- 350cells/uL.3   In 2005 the CIPRA HT 001 
study was done in Port-au-Prince, Haiti. Eight hundred and sixteen volunteers with 
CD4 counts between 200 and 350cells/uL were randomized to either start ART 
immediately or defer until their CD4 count dropped below 200cells/uL, the current 
standard in Haiti. The Data Safety Monitoring Board stopped the trial in May 2009 
when it found clear evidence favouring the earlier treatment group. In the immediate 
group six people died versus 23 in the deferred group.  Twice as many people 
contracted tuberculosis in the deferred group and these results are statistically 
significant. 4 
Francois Venter presented three pertinent issues affecting the discussion for the 
adult ART programme on when to start at the symposium at IAS 2009.2  
1. In developed countries, the average patient initiates treatment with a CD4 count of 
150 to 200cells/uL. In Sub-Saharan Africa the CD4 count for initiation has increased 
from 50cells/uL to about 100cells/uL. Venter pointed out that this was despite a large 
increase in testing in South Africa over the same period, with only about 20% of 
tested patients eligible for ART according to current guidelines. 
2. Many people die waiting for treatment. For example, of 4570 patients followed up 
for at least one year in a cohort in Free State Province, South Africa, 53.2% died. Of 
these, 87% died before receiving ART. The challenge is to decide whether treatment 
should start (irrespective of CD4 count) earlier to reduce non-AIDS morbidity. 
3. Earlier ART will have an effect on the outcome of opportunistic infections. There 














resource poor settings. Additional concerns in resource –poor settings about 
opportunistic infections are related to the high burden of tuberculosis. There were 
also concerns about the greater risk of bacterial and fungal infections including 
cryptococcal meningitis, pneumococcal infection, salmonella, and malaria, even at 
higher CD4 counts. 
Venter’s analysis provides an excellent summary of the complex issues affecting
when to start. His presentation shows that problems with systems are at least as
important as changing guidelines. Even in developed countries many patients start 
late, being well within the guideline recommendations. The situation is much worse 
in resource-poor settings. The proposed study at the sub acute wards of McCord
Siyaphila centre was done using current guidelines of the national South African
ART rollout plan. However the main research question deals with a description of the
inpatient ART model of care that will enable the clinicians to reduce the mortality
among very ill patients admitted to the medical wards. The inpatient programme has 
the potential to reduce the mortality that is due to the long delays common to the
outpatient ART model.
Revised ART guidelines. 
In late 2009, both the Department of Health and Human Services (DHHS) in the USA 
and WHO guidelines raised the CD4-cell-count threshold for starting treatment. For 
the  past several years, the results of several large cohort studies  have shown that 
starting ART at CD4 counts of 350 cells/uL or even higher would protect against a 
variety of adverse outcomes.3 The DHHS now suggests starting treatment when 
















the threshold. 5,6  New WHO recommendations endorse earlier ART initiation for HIV- 
infected adolescents and adults and an even more aggressive approach for those co 
infected with tuberculosis or hepatitis B virus. 
Meanwhile, in the developing world, treatment is seldom initiated until CD4 counts 
drop below 200 cells/ uL or clinical AIDS develops. Previous WHO guidelines have 
taken a cautious approach to HIV treatment because of the lack of resources and 
clinical infrastructure in many of the most severely affected countries. These new 
recommendations are much more aggressive, reflecting the latest evidence on the 
benefits of early treatment. Still, in many resource-constrained settings, practitioners 
have not yet been able to widely adopt the standards set by the WHO in 2006 and 
will therefore find it challenging to implement the new recommendations. 
 Clearly a progressive approach will be needed, with incremental implementation 
according to the availability of resources and the potential impact of individual 
strategies on morbidity and mortality. Of course, these findings that led to change of 
guidelines address only some of the challenges. Studies of the cumulative, long-
term, treatment-related side effects associated with early versus late ART will supply 
information to address the other challenges. Each patient’s personal risk-benefit 
calculation will continue to weigh heavily in all treatment decisions. 
The national recommendations of 2009 for expedited ART includes adults with a 
CD4 < 100 cells/uL, adults with unexplained ongoing loss of weight, pregnant women 
qualifying for ART, and adults recently hospitalised with an HIV-linked condition 

















Stages of HIV/AIDS disease 
The human immunodeficiency virus (HIV) infection is primarily an infection of the 
immune system and over a number of years destroys the cells of the immune system 
especially the CD4 T-lymphocytes (helper) cells and thus causes the acquired 
immune deficiency syndrome (AIDS).The HIV/AIDS pandemic has resulted in a high 
rate of morbidity and mortality and at present the highest prevalence of people living 
with HIV are in sub-Saharan Africa. The medical aspect of the disease due to an 
immune deficient system renders the patient vulnerable to opportunistic infections 
(OI) and malignancies. The psychosocial aspects of the disease have also to be 
considered as it is associated with stigma. Many patients at McCord hospital seek 
medical attention only when the disease is far advanced because of stigma and a 
poor family support system. The WHO staging system which assesses the immune 
system is based on the clinical condition of the patient and it divides them into four 
stages. As most patients present in stage 3 and 4 of the disease it is important to 
know the clinical staging system. (Appendix 1) 
Effect of the HIV/AIDS pandemic in public hospitals in Durban, South Africa  
The HIV/AIDS pandemic has posed a number of challenges to the health care 
system in South Africa, especially in the care of patients who are in stage four of the 
disease and hospitalised for an opportunistic infection (OI). Patients often require 
prolonged hospitalisations for the treatment of the opportunistic infection. ART is the 
only recommended treatment for HIV /AIDS and arrests morbidity and mortality 
effectively. Over the past decade, HIV infection has become the most significant and 
















comprehensive approach to treatment and care starting in 2003-2004.8  The 
province of KwaZulu-Natal and particularly its largest city, Durban, have been 
especially affected, where the prevalence of infection is estimated to be between 
31.8-40.8%. 9   A proportion of these patients present for the first time to the acute 
care medical services with advanced HIV/AIDS disease.  Durban, the largest city in 
KwaZulu-Natal has only seven public hospitals that care for the patients seeking 
admission to the hospitals. 
The McCord –Siyaphila centre in Durban.  
McCord Hospital is located in central Durban and was established in 1909 as a 
missionary hospital to care for Zulu patients. It is now a semi-private district level 
hospital that has developed a comprehensive HIV/AIDS care and treatment 
programme to care for patients at all stages of their illness. Approximately 50% of 
the admissions to the medical wards are HIV patients in stage four of the disease. 
There are only 45 beds in the medical wards, with the average length of stay being 
ten days. This constrains the number of new patients that can be admitted daily and 
may also lead to the premature discharge of patients from the acute medical wards. 
Therefore a new palliative care centre, Siyaphila (meaning “We are well” in Zulu), 
was commissioned at McCord Hospital in May 2006 to provide sub-acute and 
ongoing inpatient care.  The value of this in-patient programme is that it is linked to 
an acute care ward and the outpatient ART clinic of the hospital. Patients who 
develop intercurrent illnesses after transfer to the sub-acute ward could be referred 
back for acute care. Patients are also seen by the same team in the ART clinic on 
discharge so that continuity of care and early management of adverse events post-
















The role of ART and the integration of palliative care and HIV/AIDS care. 
 Palliative care as defined by the WHO is an approach which improves the quality of 
life of patients and their families facing life-threatening illness. Care is provided 
through the prevention, assessment, and treatment of pain and other physical, 
psychosocial, and spiritual problems. In the past palliative care was considered as a 
last resort and the patient either had disease specific treatment or palliative care. 
This was an ‘either/or’ scenario. Comprehensive palliative care in the context of 
HIV/AIDS, integrates palliative care in the continuum of care together with disease 
specific or disease-modifying treatment. This is the ‘both-and’ scenario.10 
The palliative care centre at Siyaphila  is able to provide this comprehensive care by 
providing both disease modifying treatment (treatment of OI and ART) and palliative 
treatment (pain and symptom control and supportive treatment addressing the 
psychological, social, spiritual, and cultural needs of the patient and family, including 
bereavement care). All medical inpatients are offered the option of being transferred 
to Siyaphila for ongoing inpatient care. 
The comprehensive inpatient model for provision of ART to very ill patients 
admitted to Siyaphila.  
Once patients have been started on appropriate treatment for the opportunistic 
infection and their condition is improving, they are transferred to Siyaphila centre. 
With the help of the multidisciplinary team (doctors, nurses, HIV counsellors, social 
worker, psychologist, dietician and physiotherapist) at the palliative care centre, 
those eligible for ART are enrolled on the ART programme. The eligibility criteria for 
















department of health guidelines (WHO stage four disease and or CD4 count 
<200cells/uL and disclosure to one person). 
In addition the Siyaphila criteria for inpatient ART initiation are: 
1) Patient resides in the greater Durban area 
2) Patient has disclosed HIV status to at least one person who could then be the 
treatment supporter  
3) Patient is able to swallow his pills 
4) Patient is able to afford staying in the palliative care centre at least for two weeks  
Patients with HIV/AIDS were triaged to receive one of the two protocols of care that 
is advocated. This was designed for use at McCord hospital by consultants in HIV 
medicine as standard of care. 11    
(1)Terminal care: Patients with the following conditions are considered for end of life 
care according to palliative care principles: irreversible end-organ damage, 
advanced malignancies and /or are unable to take oral medication for various 
irreversible medical reasons. Among the diagnoses were: end stage renal disease 
with multiple co morbidities, advanced malignancies (Kaposi’s sarcoma, lymphoma, 
carcinoma of the cervix), intractable cardiac failure with cardiomyopathy, pulmonary 
hypertension with poor prognosis, severe soft tissue sepsis and complicated central 
nervous infections with poor prognosis. 
(2) Sub-acute and ongoing care of treatable clinical conditions: Treatment for 
















therapy (ART), which is the cornerstone of palliative care in AIDS, is offered to 
patients who are eligible as described in the Siyaphila criteria above. 
Siyaphila centre offers a package of healthcare that is patient-centred and 
comprehensive to incorporate the following components: 
Clinical Care: This involves ongoing treatment of the OI until the patient has 
recovered sufficiently to become physically independent. ART is then provided from 
the first line regimen recommended by the department of health being Stavudine, 
Lamivudine and Efavirenz. The interdisciplinary team consists of doctors practicing 
different medical specialties. This expert multidisciplinary team approach expedited 
the care of the clinical problems and enabled patients to go onto ART earlier. A 
palliative care physician trained in HIV medicine worked closely with a specialist 
family physician who was also trained in HIV medicine  and  infectious disease 
physician .The infectious disease specialist and specialists in other fields of internal 
medicine were available for consultation at all times. ART initiation was expedited 
because of the skills of the medical team. 
Spiritual Care: Consistent with the priority to treat total pain, a team of trained 
counselors and spiritual care givers help the patients deal with spiritual issues that 
cause them distress.    
Psychological Care:  A team of psychologists with a visiting psychiatrist assist 
patients to overcome psychological barriers in their care before and after ART 
initiation. Cognitive function and AIDS related dementia is also assessed before and 
after ART initiation.  
Social Care: Patients and their families require various types of care including, 
















individuals and family members to maintain links to care services. Support group 
services are also provided on site.   
Physical Rehabilitation: Physical therapy and nutritional interventions are very 
important for successful rehabilitation. 
End of Life Care: Symptom management, supportive care through the patient’s 
terminal phase of HIV/AIDS illness is provided by the interdisciplinary team. 
Bereavement counseling for the family is commenced and appropriate follow up 
done. 
HIV Counseling Services: Trained lay HIV counselors are involved in ART literacy 
training before and after ART initiation. Group sessions are held with the entire 
interdisciplinary team before discharge of patients. 
Community support and follow up: Those who are not eligible for ART are 
discharged to care providers and programmes in the area where they reside. The 
Sinikithemba (“we give hope “in Zulu) ART clinic at Mc Cord hospital is available to 
all patients commenced on ART at Siyaphila. Support group services at the hospital 
provide ongoing support.  
Conclusion.  
The delay in ART initiation due to long waiting lists in the clinic and the high mortality 
from this delay are important issues to be addressed. Another system of care like an 
inpatient expedited initiation programme that provides ART for the very ill patients 
will be described in this proposed study. A pilot study described below was done at 
McCord hospital on patients discharged from the acute medical ward. This study was 
the basis to do further work to provide expedited ART to very ill patients.    
Furthermore, the guidelines to start ART at CD4 counts <350 will further reduce the 
















by the department of health. However the expedited ART programme for certain 
categories of patients with CD4 <200 cells/uL are already approved by the 
department of health in 2009. 5 
AIMS AND OBJECTIVES OF RESEARCH  
Aims   
To analyse an inpatient programme for early ART initiation after diagnosis of 
opportunistic infections as well as 24 week outcomes. 
Objectives 
The objectives were  
1) To determine the number of patients initiated on early ART who would otherwise 
have ART delayed. 
2) To estimate the prevalence of adverse events, including IRIS. 
3) To describe clinical and biochemical outcomes at six months. 
4) To determine the rates for mortality and lost to care among patients enrolled. 
5) To determine the predictors of early mortality. 
6) To make recommendations to develop a protocol and system of care for early 


















        LITERATURE REVIEW 
 Sources and purpose of review. 
The literature search focused on the review of articles to assess the efficacy of 
expedited ART in very ill patients after the diagnosis of an opportunistic infection. 
The second challenge was to examine different systems of care to provide ART for 
patients admitted to a health centre. Literature review for international and South 
African articles was done by computer search using the key words “inpatient ART”. 
Data from randomized controlled trials 12,13  and from the case controlled study done 
in an academic hospital in Cape Town 1 and several observational studies 14,15,16 are 
cited below. The randomised controlled studies showed good validity of the results 
when comparing the early and deferred ART groups. The case controlled study also 
compared two groups who initiated ART early, but in different settings. The data 
analysis showed good scientific rigor.  However all these studies demonstrate the 
improved mortality outcomes after inpatient ART initiation. The prevalence of 
opportunistic infections differed between developed and developing countries and 
thus the search for local data from South Africa was an important aspect of the 
review. 
 Pilot study describing a historical control group at Mc Cord Hospital. 
In a pilot study done by Murphy et al in an inpatient population group in 2006, the 
mortality rate was 52 % in patients discharged after treatment for an acute OI who 
did not access ART within four months. 17 The barriers to access ART in this study 
was not clearly described. However mortality was associated with lower CD4 count 
















In this study including 49 patients conducted at McCord Hospital between December 
2006 and August 2007, the researchers evaluated ART uptake (secondary outcome) 
and mortality (primary outcome) six months after admission for an acute OI.  For the 
20 patients (44%) who initiated ART, the median time from discharge to commencing 
an ART regimen was 82 days. Among the 25 patients (56%) who did not initiate 
ART, 13 died (mortality 52%). Overall, two-thirds of patients with higher entry level 
CD4 counts (50 –200 cells/uL) successfully accessed ART after receiving treatment 
for an OI versus 32% of patients with lower entry level CD4 counts (<50 cells/ uL) 
(p=0.06). Failure to initiate ART after admission for an OI was associated with an 
almost 13 fold increased risk of death. 
The effect of ART soon after the diagnosis of various opportunistic infections 
common worldwide. 
 ART reduces overall mortality among persons with HIV-1infection. According to the 
Morbidity and Mortality Weekly Report (MMWR) of the Centre for Disease Control, 
Atlanta  18  dated 2004, providing ART in the setting of acute OIs has advantages that 
outweigh the disadvantages. ART initiation is especially indicated in the setting of 
acute OIs for which there is no known alternative treatment options. Kaposi’s 
sarcoma (KS),16  chronic diarrhoea caused by cryptosporidiosis and 
microsporidiosis,17 and progressive multifocal leukoencephalopathy (PML),18 have 
been shown to respond to ART and guidelines recommend immediate ART initiation.  
The timing of initiation of ART in the setting of acute OI is currently an area of great 
interest. There is some concern for potential drug-drug interactions, toxicities and 
















condition of the patient.18  In Uganda, Bisson G. et al demonstrated better outcomes 
in starting ART together with treatment for cryptococcal  meningitis.19 Zolopa A. et al 
demonstrated the improvement in mortality rates for inpatients starting ART within 
two weeks of diagnosis of OIs.12  This group was compared in a large, multicentre, 
randomised controlled trial to a group that started ART treatment two months after 
the diagnosis of an OI. The OIs treated were pneumocystis pneumonia, cryptococcal 
meningitis and toxoplasmosis. However patients with tuberculosis were not included 
in this study. 
Studies that describe the timing of early ART after diagnosis of opportunistic 
infections common in South Africa. 
The study in South Africa by Faesan S. et al also confirmed that the presence of TB 
at the start of ART did not adversely affect outcomes. 20   Other studies cited below 
demonstrate the relative safety of treating the most common opportunistic infections, 
namely cryptococcal meningitis and tuberculosis in South Africa, with ART early in 
the course of the disease, within weeks rather than months. Additionally, they 
conclude that the presence of an OI is not an absolute contraindication to start ART 
early. Lawn SD et al, in Cape Town described the challenges of the outpatient model 
of ART provision 21 in a study that followed patients for 34 days after enrolment. In 
the programme pre-treatment and early treatment deaths together accounted for 
87% of deaths and were independently associated with advanced immunodeficiency 
at enrolment. The possible causes of late access to the ART programme were 
identified as: delays in health care access, health system delays, or inappropriate 
















To address the question of timing of ART in TB, which is the commonest 
opportunistic infection in South Africa, a trial by the Centre for AIDS Programme of 
Research in South Africa was reported in 2008.13   The Starting Antiretrovirals at 
three Points in TB (SAPIT) study supports the use of early ART in patients with acute 
OIs (within two months) after initiation of anti tuberculosis treatment irrespective of 
CD4 count. HIV and TB co-infected patients assigned randomly to receive ART, 
together with their TB treatment (integrated arm), were compared to patients 
assigned to receive ART upon completion of TB treatment (sequential arm). There 
was a mortality rate of 11.6 per 100 person-years in the sequential arm compared to 
the mortality rate of 5.1 per 100 person-years in the integrated arms. The early 
integrated arm started ART as soon as possible within the first two months of TB 
treatment and the late integrated arm started ART as soon as possible after 
completing the two months intensive phase of TB treatment. The ideal timing of 
initiation of ART to maximize benefit and minimize morbidity and mortality remains 
unclear but would appear to be within the first months of initiating anti-tuberculosis 
treatment. 
 
 Initiation of antiretroviral therapy (ART) is often delayed in patients with newly 
diagnosed AIDS and tuberculosis (TB), to avoid immune reconstitution inflammatory 
syndrome (IRIS) and a tangle of possible drug interactions and adverse effects. 
However, results from the CAMELIA trial 22in Cambodia add to the growing body of 
evidence indicating that earlier ART is better. A total of 661 HIV-infected, ART-naive 
patients with smear-positive TB and CD4 counts <200 cells/uL (median, 25 cells/uL) 
were randomized to initiate Efavirenz + Stavudine +Lamivudine  either two  weeks or 
















mortality was 34% lower in the early-ART group than in the late-ART group, and a 
multivariate 
analysis confirmed that late receipt of ART was an independent predictor of 
death. Among survivors, the virologic efficacy of ART was excellent in both groups. 
 
These results confirm and extend the findings described above, of two other 
important trials: ACTG A5164, which showed the importance of early ART during  
treatment for opportunistic infections other than TB 12,and SAPiT, which showed that 
integrating ART into TB treatment is better than deferring it until after TB treatment is 
complete.13  The analysis of early versus late ART in SAPiT is still pending, but one 
wonders whether simultaneous initiation of HIV and TB treatment could reduce early 
mortality rates even further. 
 
IRIS and the effect of timing of ART 
 
IRIS was found to be more common in the early treatment arm compared to the late 
treatment arm in most recent studies .12,22  However there were no deaths from the 
IRIS event  The benefits seem to outweigh the risks of IRIS. What is required is 
clinical vigilance and sound management strategies. Treatment of the OI early 
together with the continuation of ART is warranted. Patient information will enable 
patients to present early for clinical assessment, especially after discharge. 
 
IRIS was not significantly different in the ACTG trial 12 between early (8/141patients) 
and deferred group (12/141patients). IRIS developed at a median of 33 days .There 
was no significant difference in IRIS between groups on steroids (6%) vs. those not 
















to defer ART. In the SAPIT T trial 13 there were no IRIS deaths, in the integrated arm 
there were 52 /429 (12.1 % ) cases of IRIS ,compared to  8 /213 ( 3.8 %)  cases of 
IRIS in the sequential arm, which was statistically significant .( p value of <0.05).Ten 
patients with IRIS were hospitalised in the integrated arm and none in the sequential 
arm. Only four patients were on steroid treatment. In the CAMELIA study 22, IRIS 
was two to three times more frequent in the early arm (p< .0001).IRIS was not 
aggressive in its clinical presentation and was relatively easy to manage. This study 
supports a much earlier (within two weeks) initiation of ART in HIV/TB compared to 
other studies.  
 
Different systems of care for the provision of inpatient ART 
Academic hospital medical wards. 
 Eshun-Wilson et al evaluated the outcomes in patients commencing ART after OI 
during hospitalisation at a South African academic hospital between January 01, 
2004 and March 31, 2008. 13 Selected patients were initiated on ART as inpatients 
among those admitted to the acute care ward. The controls were patients who 
attended the infectious diseases outpatient department during that period. Forty 
eight patients (80%) were admitted with AIDS-defining illnesses, the commonest 
admission diagnoses were Kaposi’s sarcoma (seven cases), tuberculosis (seven 
cases), and non-Hodgkin’s lymphoma (six cases). Eleven patients died before 
hospital discharge and six before follow up appointment. In the case-control analysis, 
patients who had been hospitalised and discharged for initiation of ARVs as 
















2.8 to 19.23) and were more likely to be lost to follow-up (odds ratio = 4.07; 95% 
confidence interval = 1.32 to 12.52). There were only 15 previously hospitalised 
patients with viral load measurements at 12 months. 
The reasons for poor follow up were the great distances that patients had to travel to 
the hospital. The patients were referred to clinics that were located far away from the 
city centre. The median CD4 count in the hospitalised group and control group was 
91 and 64.5 cells /uL respectively .The commonest AIDS-defining illnesses in the 
outpatient group were disseminated tuberculosis (19 cases) and oesophageal 
candidiasis (11 cases). It was established that there was a higher mortality among 
hospitalised patients, as these patients were admitted due to the severity and extent 
of their illnesses. 
 The high numbers lost to follow up among patients discharged from the hospital 
wards was noteworthy. Previous studies had suggested that up to 50% of patients 
who are lost to follow-up in low-resource settings have died.22   Patients who had 
been initiated on ART while in hospital and who returned for follow-up and remained 
on ART had favourable treatment outcomes. This is similar to the findings by Soria A 
et al, 23 which showed good virological outcomes and adherence in an Italian cohort 
of patients commencing ART during hospitalisation. However, both studies are small 
making it difficult to draw meaningful conclusions from the results.  Patients 
discharged from the wards who do remain in care have comparable treatment 
outcomes to those of more clinically stable patients. It will be ideal to place the very 
ill patients in a programme linked to a home-based care network. An improved 
system for patient follow-up and earlier initiation of ART was recommended to 

















ART in an intensive care unit  
It is possible to provide patients that are admitted in an advanced stage of disease 
with ART in the intensive care unit (ICU). A retrospective study conducted in Brazil 
adds to the evidence supporting early ART in patients with acute OIs. 24 This study 
suggests that those benefits might begin to accrue even sooner. The study involved 
278 HIV-infected patients who were admitted to a Brazilian intensive-care unit (ICU) 
between late 1996 and late 2006. Eighty percent had AIDS-defining conditions, with 
the most common opportunistic infections being tuberculosis and pneumocystis 
pneumonia. The use of ART in the ICU (whether initiated then or previously) was 
associated with a 50% reduction in six month mortality; the benefit was statistically 
significant only if ART was used within the first four days after ICU admission. 
Survival curves for patients who initiated ART in the ICU versus those who did not, 
diverged within the first 25 days after admission; subsequently, similar numbers of 
patients died within each group. The rate of IRIS that was detected in the ICU was 
quite low (~1%), but this may be related to the difficulty of identifying IRIS in critically 
ill patients in a retrospective study. Mortality rates were high both in the ICU (55%) 
and six months after admission (69%). The benefit of ART in the ICU setting seemed 
mainly to be to improve survival rate at six months. 
Palliative care inpatient unit. 
Jameson described the success of an inpatient palliative care unit in treating both 
patients with cancer and HIV.26  The inpatient unit was developed as a public-private 
partnership in Grahamstown to address the problems of the two diverse groups in 
the community; the affluent, elderly patients with cancer and the younger, often 
















admitted to the palliative care unit in the first three months following the opening of 
the ward (1 March-31May 2006). Of these patients, 36 (70%) had AIDS and 15 had 
cancer (30%).Patients had to fulfil the criteria of being a hospice patient and also 
have a primary care giver at home to care for the patient on discharge. Criteria for 
hospice care for HIV/AIDS patients include all patients in stage 3 or 4 disease and 
not only terminally ill patients. These patients require ongoing treatment for AIDS 
defining conditions and symptom management. The patients were admitted from the 
HIV clinic, medical ward and the hospice. The palliative treatment involved pain and 
symptom relief with the use of morphine for pain, dyspnoea, and diarrhoea, 
haloperidol for nausea and confusion, non-steroidal anti-inflammatory drugs  for 
pain, lorazepam for anxiety and other medications commonly used in the palliative 
care setting. All AIDS patients were on ART. The outcome in 16 cases was death (6 
had cancer).The AIDS patients stayed longer (average length of stay being 8.3 days) 
because of side-effects to ART or immune reconstitution syndrome (IRIS) as 
compared to the cancer patients (average length of stay being 3.8 days). The death 
rate in the first 3 months was 38% in the cancer patients and 33% in the AIDS 
patients. In the following two months the death rate was 33% in the cancer patients 
and 19% in the AIDS patients. Though the numbers were small the drop in the death 
rate may be related to earlier initiation of ART and application of palliative care 
principles in the treatment of AIDS patients. Larger studies are needed to establish 
the mortality benefit of early ART initiation. 
Inpatient community health centre.  
The Keiskamma AIDS Treatment (KAT) Programme was established in Hamburg, 
















routine work in the local primary clinics. People living with HIV/AIDS who are too sick 
or too poor to access facility based resources were able to get ART through the 
Keiskamma AIDS Treatment Programme. 27 The study followed the progress of 174 
patients in the period from July 2004 to February 2006. Members of the community 
were employed as nursing staff, caregivers, community health workers and drivers. 
Due to the remoteness and economic conditions of the communities, the 
effectiveness of the KAT Programme depended on three key components: 1) 
availability of in-patient facilities, 2) transportation and 3) a network of home- based 
care workers. 
Keiskamma AIDS Treatment centre was established in an old house with 20 beds 
and patients stayed for one to two weeks and were educated about their illness and 
ART. Many of the patients were very sick and unable to care for themselves. Those 
who had an opportunistic infection were treated where possible. A high proportion of 
patients had TB. Patients left the centre once they had started ART. Transport was 
provided through two light delivery vehicles with drivers who not only brought 
patients to the Keiskamma AIDS Treatment centre but also took patients to the 
secondary and tertiary facilities for specialist consultation. The home- based care 
workers were able to monitor adherence in the communities and provide contact with 
the Keiskamma AIDS Treatment centre. 
The study classified the 174 patients as ambulant or bedridden, CD4 count at 
treatment initiation was taken as baseline CD4. Possible patient outcomes at six 
months were: 
















2) Poor response -VL >400 copies /ml or CD4 count <250 cells/uL  
 3) Died 
 4) Lost to follow up 
5) Insufficient data 
 6) transferred out (to other ART programmes.) 
Most of the patients were female (74%) and about half were bedridden (42%) which 
makes a programme like this very beneficial in communities that are in the lower 
socioeconomic group. Baseline CD4 counts reflected that most of the patients had 
very advanced immunosuppression. Thirty seven percent were in the range of 0 -49 
cells/uL and 26 % were in the range of 50 -99 cells/uL. Only 11 % had CD4 cells > 
200 cells/uL. Of the patients with baseline CD4 counts 0-99 cells/uL, 56 %were 
bedridden and unlikely to have accessed conventional facility-based care. Although 
more bedridden patients died (43%) compared to ambulant patients (5%) the 
outcome was still considered as successful as the bedridden patients were 
extremely ill at treatment before the ART had therapeutic effect. The success of the 
programme was probably linked to the in-patient facility where ART counselling 
could be done and patients made ready for ART. The transport system made it 
possible for those who needed it most (the sickest and the poorest). The community 
health workers played the key role by providing an extensive support network. 
Community based ART programmes can be useful adjuncts to the facility based 
system. Effective treatment programmes must address the needs of the community. 
The study also provided evidence that no one should be regarded as too sick to 
















care and thus the necessity to work within the Government HIV/ART programme for 
sustainability.   
Conclusions. 
The literature review supported the efficacy of ART early in the course of stage four 
disease; especially after diagnosis and treatment of an acute opportunistic infection. 
However all these studies were reported on small numbers of patients and were 
done at a time when there was limited evidence for the efficacy for early inpatient 
ART initiation in very ill patients. The majority of HIV/AIDS patients are admitted to a 
district level public hospital in South Africa. This type of programme has not been 
established as a standard of care in this setting. There was a high early mortality 
when patients were discharged from the acute care wards with no access to ART 
within the first few months. The outpatient programme linked to some hospitals has 
several challenges to deal with very ill patients as well as a limitation on the numbers 
that could be seen in the clinic. Various inpatient programmes have been described 
which were based in the ICU, academic hospitals, community health inpatient 
centres and palliative care wards. What would be the best inpatient programme will 
depend on the needs of the community served by the programme. Thus, the 
rationale for the proposed study was to describe a unique system of care that is 
suitable to deal with the early provision of ART to very ill patients admitted to a 
district level public sector hospital. 
Though AIDS has become a chronic manageable disease, because of ART, the 
morbidity and mortality remains high. A dynamic and integrated framework of both 
















throughout the course of their illness. Decisions regarding the goals of care with 
respect to medical and psychosocial issues need to be more collaborative with 
patient focussed care.28 
Thus a successful palliative care programme needs to have a national policy to 
ensure good standards, funding for education and training of health care workers 



















                                           METHODOLOGY 
Study Design 
The study was a quantitative retrospective analysis through review of clinical 
records, of a cohort of HIV positive inpatients who were initiated on ART after the 
diagnosis of an OI.  
Study Site  
The study site was a palliative care centre (Siyaphila) attached to McCord hospital in 
Durban and the outpatient clinic, Sinikithemba.  
Study population and sampling 
The study population consisted of HIV positive patients admitted to Siyaphila from 
the acute care medical ward of Mc Cord hospital to which they had been admitted 
with the diagnosis of an acute opportunistic infection.  
The study cohort was chosen as a convenience sample. The study sample consisted 
of the first consecutive 100 patients who were initiated on ART at Siyaphila between 
November 2006 and May 2007. Three hundred and fifty eight patients were admitted 
during this period. 
Data collection: 
Data extraction sheets 
















1) Initial data collection at time of admission (Appendix 2) 
2) Six month follow up data collection sheet (Appendix 3) 
The researcher developed the set of questions that were relevant to the study in 
consultation with colleagues and supervisor. The important data to be collected was 
formulated in order to answer the key research objectives. Demographic data and 
baseline clinical and laboratory data were needed to be compared with outcomes at 
six months. The optimal time for ART initiation was a key measurement and thus the 
time lines for admission and discharge were crucial. A record of the clinical progress 
before and after discharge was enumerated according to anticipated adverse events 
associated with the ART regimens used.  
The researcher developed the initial and a follow up data sheet in consultation with 
the consultant of Medicine at McCord hospital. The source of data for the initial data 
collection sheet was the inpatient notes and discharge summary. The discharge 
summary was designed by the clinicians as a standard of care document for all 
inpatients to facilitate the handover of patients to the next level of care. The main 
source for the follow up data was the electronic patient record system used in the 
outpatient ART clinic at McCord hospital. Data recorded in the electronic records 
were consistent with department of health guidelines. It recorded clinical, 
immunological and biological outcomes mainly. Other laboratory data was limited to 


















Data collection process. 
 Data was collected by the researcher from the hospital database comprising of the 
inpatient files and discharge summaries from Siyaphila for the initial data sheet. The 
data was recorded for the first 100 patients who started ART. For the six- month 
follow-up data, the electronic patient record (EPR) and the patient files from the 
outpatient ART clinic Sinikithemba (“We give hope” in Zulu), was used. The 
incidence of missing data was to be minimized by searching for information in all 
three records: the inpatient file, the electronic patient record and the outpatient file.  
 VALIDITY AND BIAS 
Measures to ensure validity of data  
Most data collection was carried out by trained volunteer research assistants who 
checked each entry twice. The consistency of data collection was ensured by using a 
customised data collection sheet as included in the appendices. 
Reduction of bias 
 Selection bias: 
All patients admitted consecutively from the acute care wards who were considered 
sick enough to be sent to Siyaphila were included in the study population. The same 
patients who were discharged were followed up by the research clinician over the six 
















Information bias:  
Data was validated by triangulating it from different sources in the hospital database 
before it was entered onto the patient data collection sheet. When information was 
missing on the electronic patient record, patient files were reviewed.  
Confidentiality 
The names of patients were not being disclosed .The data collection sheets were 
numbered. The data collection forms were identified by unique number ensuring 
anonymisation of the data. 
Data analysis  
An Excel spread sheet and Access database were created by a research 
assistant to record and identify key clinical and laboratory data at baseline 
and at six months for each patient. Data analysis was done using a standard 
statistical package.  The statistical package used was the SPSS (Version 
19.0, Chicago, IL). 
The final outcome measures were: mortality at 24 weeks and virological and 
clinical outcomes including clinical complications. at 24 weeks. 
Other data analysed were: 
1. Demographic data, 
2. Prevalence of different types of OIs, 
















4. Prevalence of adverse events on ART, 
5. Prevalence of different types of IRIS and 
6. Clinical markers.  
Ethical considerations 
 Consent  
All patients joining the ART programme at Sinikithemba signed a contract as part of 
the help expand ARV therapy (HEART), a President’s Emergency Plan for AIDS 
Relief  (PEPFAR) initiative, consenting to the use of clinical information for research. 
Data was extracted from hospital database of patient records. Patients were not 
identified from the records. Permission from the medical superintendent at McCord 
hospital was obtained (Appendix 4)  
 Privacy 
 The data collection sheets were stored in a locker in the researcher’s office. 
Information linking patients to the forms were kept in a separate site from the 
research data. The identity of the patient was not known to the research assistant 
who did the data entry, and thus the privacy of the patient was respected.   
 Ethics approval 
Application to the Mc Cord Hospital Research Ethics committee. (Appendix 5) 
















                                     RESULTS 
Three hundred and fifty eight patients were referred from the acute care medical 
wards of Mc Cord Hospital to Siyaphila centre. Only 93 patients (26 % of those 
admitted) were started on inpatient ART and were found to be eligible for analysis. 
Seven patients were excluded from the study because they had initiated ART at 
other sites and were changing service provider from other sites to McCord hospital. 
(Figure 1). 
 Figure 1 Inclusion of first 100 patients in immediate ART after OI diagnosis 
and discharge from the acute medical wards of Mc Cord Hospital to Siyaphila 











100 Assessed for eligibility for 
immediate ART 
93 Initiated immediate ART 
64 Assessed at 24 weeks 
19 Died during 24-week follow-up 








 Inpatient ART initiation 
14 Died after ART initiation and 
discharge 
6 Were lost to follow-up 
 
4 Changed service providers during 
follow-up 

















Table 1(A): Baseline characteristics of first 100 patients at the time of OI when 
admitted to the acute care wards from November 2006 to May 2007. 
The median age in the cohort was 37 years and women constituted 45 % of the 
cohort. The majority of the patients were of black ethnic background (90 %). The 
median baseline haemoglobin was 9.9 g/dl (IQR 8.2 -11.3). The median baseline 
albumin was 25 g/l (IQR 20 -29). (See Table 1A) 
Demographics and weight Patients N=93 
Median Age (years) [IQR] 37 [31-45] 
Women no. (%) 46 (49) 
Ethnicy no. (%)  
Black 84 (90) 
Non-black 9 (10) 
Median baseline weight (kg) [IQR] 2 54 [47-60] 
Baseline weight < 45 kg – no. (%) 14 (15) 
Other baseline laboratory parameters   
o Median baseline hemoglobin (g/dl) [IQR] * 9.9 [8.2-11.3] 
o Median baseline albumin (g/l) [IQR] * 25 [20-29] 




















Table 1(B): Baseline characteristics of first 100 patients at the time of OI when 
admitted to the acute care wards from November 2006 to May 2007. 
Acute OI- no. (%) N= 93 
Tuberculosis  
o Pulmonary 15 (16) 
o Extrapulmonary 34 (37) 
o Meningitis 10 (11) 
Cryptococcal Meningitis 12 (13) 
Pneumocystis  neumonía 10 (11) 
Chronic diarrhoea (>14 days) 4 (4) 
Toxoplasmosis of the brain 4 (4) 
Bacterial pneumonia  3 (3) 
HIV-associated cardiomyopathy 1 (1) 
Median baseline weight (kg) [IQR] 2 54 [47-60] 
Baseline weight < 45 kg – no. (%) 14 (15) 
 
Tuberculosis was the commonest OI, seen in   63 % (n=59) of the patients of 
which15/93 had pulmonary TB (16 %), 10/93 patients had TB meningitis (11%) and 
34 /93 had other extra pulmonary TB (37 %). The diagnosis in the remaining 41 % 
were cryptococcal meningitis  (13%),  pneumocystis  pneumonia (11%), chronic 
diarrhoea (4%),  toxoplasmosis of the brain (4%), bacterial pneumonia (3%) and  HIV 


















Table 1(C): Baseline characteristics of first 100 patients at the time of OI when 
admitted to the acute care wards from November 2006 to May 2007. 
 Other clinical characteristics  
Median baseline CD4 count (cells/uL) [IQR] 21 [9-44] 
Baseline CD4 cell count category (%)  
0-49 cells/ul 69 (76) 
50-99 cells/ul   11 (12) 
100-199 cells/ul 10 (11) 
200-349 cells/ul 1 (1) 
Acute OI- no. (%)  
 
The median CD4 cell count in this group was 21cells/uL. The majority of the patients 
















Table 2(A): Initial 24-week outcomes after immediate ART commenced at 
Siyaphila from November 2006 to May 2007. 
Outcome  Patients N=93 
 
Timing of ART initiation achieved     Median days 
from admission with OI to ART initiation – no. [IQR] 
 
15 [12-20] 
     ART regimen initiated no. (%)  
        D4T – 3TC – EFV 92 (99) 
        D4T – 3TC – NVP(Nevirapine)  1 (1) 
     24-week Virological Outcomes   
   Intent-to-treat viral suppression <400 c/mol no, (%)  54 (58) 
    As-treated (AT) viral suppression <400 c/mL no. (%)  54 (92) 
24-week Immunologic Outcomes   
   Median CD4 count improvement (cells/uL) (IQR)  90 (49-156) 
   CD4 cell count > 100 cells/uL at 24 weeks, no. (%)  41 (66) 
24-week Weight Gain, kg. (IQR)  8.0 (3.3-14.6) 
 
Thirty eight patients (40%) were started on ART within two weeks of an OI diagnosis. 
The median days to ART initiation from admission with an opportunistic infection 
were 15 days (IQR 12 -20). Most of the patients (99%) were commenced on 
Regimen 1 a consists of Stavudine (D4T), Lamivudine (3TC) and Efavirenz (EFV). At 
twenty four weeks, the intent to treat viral suppression (< 400 copies/ml) was 58 % 
seen in 54/93 patients. The viral suppression in the as treated group of 54/93 
















90 cells/uL (IQR 49 -156). Fourty one (66%) of the patients on ART achieved a CD4 
count of >100 cells/uL. The median 24 week weight gain in the group was 8 kg. 
(Table 2 A) 
The overall mortality rate at 24 weeks among the 93 patients was 20% (95%CI 13-
29%).Fourteen patients (15 %) died after discharge and 5 died prior to discharge 
from Siyaphila (5%). A median day to death in all patients was 51 days (IQR 16 -
106).There was a loss to follow up of 6% and four patients (4%) changed service 
provider .(Table 2B)  
Table 2(B): Initial 24-week outcomes after immediate ART commenced at 
Siyaphila from November 2006 to May 2007. 
24-week Vital Outcomes N =93 
   Overall mortality (%)  19 (20) 
   Mortality before Siyaphila discharge  5 (5) 
   Mortality after discharge 14 (15) 
   Median days to death, (IQR)  51 (16-106) 
24-week Programme Outcomes   
   Loss to follow-up (%)  6 (6) 




















Table 2(C): Initial 24-week outcomes after immediate ART commenced at 
Siyaphila from November 2006 to May 2007. 
Serious IRIS Events and Adverse events N  =93 
 IRIS events requiring admission, no.  (%)  7 (8) 
  Tuberculosis 5 (5) 
  Cryptococcal meningitis 2 (2) 
  Pneumocystis  pneumonia 1 (1) 
   IRIS-associated deaths  1 (1) 
 Change to Zidovudine (AZT)-3TC-EFV no. (%) 13 (14) 
 Peripheral neuropathy 9 (10) 
 Lactic acidosis 1 (1) 
Pre-emptive switch with an increase in BMI to >28 kg/m2 1 (1) 
 Change to D4T-3TC-NVP  
 Neuropsychiatric event 2 (2) 
 
Adverse events were managed at an outpatient level and seven patients (8%) 
required admission for IRIS. The details of how these patients with IRIS presented is 
not known, however there was only one death in this group out of 8 patients. Five 
had tuberculosis, two had cryptococcal meningitis and one had pnuemocystis 
pneumonia. Most TB IRIS cases were self-limiting. One patient who had IRIS 
cryptococcal meningitis died. Thirteen patients (14%) changed regimen by six 
months to Zidovudine, Lamivudine and Efavirenz. The main reason for change was 
















Table 3(A) : Univariate Analysis of Factors Associated with 24-Week Mortality 
after Acute OI and ART initiation in the first 100 patients at Siyaphila from 
November 2006. 
Characteristics N no. (%) P 
All subjects 93 19 (20)  
Ethnicity    
     Black 84 17 (20)  
     Non-Black 9 2 (22) 0.7 
Gender    
     Female 46 5 (11)  
     Male 47 14 (30) 0.03 
Age    
     0-29 years 21 3 (14)  
     30 – 39 years 38 6 (16)  
     40 – 49 years 26 7 (27)  
     > 50 years 8 3 (38) 0.4 
Initial CD4 cell count     
     0-49 cells/ul   69 14 (20)  
     50-99 cells/ul   11 2 (18)  
     100-199 cells/ul  11 2 (18) 0.9 
 
A univariate analysis was performed to assess risk factors associated with 24 week 
















ethnicity, gender and age were assessed as risk factors. Only male gender was 
predictive of higher mortality (30 % for males vs. 11 % for females) and was 
statistically significant (p <0.03).Baseline CD4 count ranges 0-49, 50 -99 and 100 to 
200 cells /uL was not predictive of mortality. (Table 3 A) 
Table 3(B) : Univariate Analysis of Factors Associated with 24-Week Mortality 
after Acute OI and ART initiation in the first 100 patients at Siyaphila from 
November 2006. 
Time from OI therapy to ART    
     0-14 days no,(%) 38 6 (16)  
     >15 days no.(%) 55 13 (25) 0.3 
Opportunistic infection     
     Tuberculosis 59 12 (20)  
     Other OI 34 7 (21) 0.9 
Hemoglobin baseline    
     <9 31 7 (23)  
     >9 59 12 (20) 0.7 
Albumin baseline    
     <20 23 7 (30)  
     21-25 28 5 (18)  
        26-30 19    4 (19)  

















Twenty four week mortality among the 55 patients started on ART after 15 days was 
25 % (13/55 patients). Only 6 out of the 38 patients who initiated ART between 0 to 
14 days died by 24 weeks (mortality 16 %).This was not statistically significant in the 
univariate analysis (p=0.3).Having tuberculosis compared to other opportunistic 
infections was also not predictive of greater mortality at 24 weeks (p =0.9).Baseline 
















                                       DISCUSSION 
Introduction 
In a pilot study done by Murphy et al 17 in an inpatient population group in 2006, the 
mortality rate was 52 % in patients discharged after treatment for an acute OI who 
did not access ART within four months. The reported results from the present study 
of a 20 % (95%CI 13-29%) mortality at six months in the ART cohort is an important 
outcome. Both the studies enrolled a similar cohort from the same hospital with a 
similar prevalence of different OIs. In this pilot study, patients were discharged 
without ART and formed the historical control group. There are no other comparable 
studies done in a district hospital.  
One study in South Africa was done on an inpatient cohort in a community health 
centre.27 More bedridden patients died (43%) compared to ambulant patients (5%). 
The outcome was still considered as successful as the bedridden patients were 
extremely ill at treatment before the ART had therapeutic effect. .In another study13 
at an academic hospital in Cape Town, 17/48 (34 %) patients among those 
hospitalised died (11 before discharge and 6 after discharge) .It is not clear to what 
extent linkage to care after discharge was appropriately arranged. for these patients. 
The discussion will focus on how the integration of palliative care with HIV care 
worked in reducing mortality in this group of very ill patients. 
The challenge of treating the sickest patients 
The literature search provides evidence that earlier ART initiation soon after 
















living with HIV/AIDS. Clinicians are often reluctant to initiate ART early due to the 
complexities of treating patients with multiple co morbidities for which they get 
admitted. Starting ART increases the pill burden, and has the potential to increase 
drug interactions and drug adverse events. This group of patients requires an 
extensive diagnostic work up and management by experienced clinicians. However, 
if clear guidelines for the timing of ART are available, more patients could initiate 
ART early.  
The challenge of the inpatient expedited ART programme is to limit treatment related 
complications in patients presenting with acute opportunistic infection. Prolonged 
hospitalisation of People Living with HIV/AIDS may be required to surmount the 
considerable barriers discussed above. One additional challenge linked with 
providing an optimal service for patients are the unique needs that each patient 
brings to the therapeutic encounter and the need for individualised attention. These 
unique needs include multiple opportunistic infections, psychosocial co morbidities, 
severe poverty, and alternative belief systems which may call into question the 
efficacy of allopathic medicines. 
The need for an appropriate follow up plan  
The Siyaphila programme describes the management of the largest cohort of 
PLWHA at a district hospital. Patients were followed up at a clinic linked to the 
hospital. This clinic is accessible by public transport to the patients who live in the 
greater Durban area. A large number of patients are lost to follow up in many studies 
















study in an academic hospital in Cape Town. Very ill patients were discharged to 
clinics for follow up that were situated far away from their place of residence.  
 The benefits of the Siyaphila follow up plan 
The inpatient stay of patients in Siyaphila after ART initiation is crucial to monitor and 
treat anticipated adverse events and drug toxicities from combined opportunistic 
infection treatment and ART. The variable time to initiate ART after initial admission 
for different clinical conditions emphasizes the need for an individualised approach 
about the optimal time to initiate ART. Different conditions and clinical presentations 
require different durations of treatment for the presenting problem. Those patients 
that have associated physical and psychosocial co-morbidities require a longer time 
for ART readiness preparation. A detailed follow-up plan was created upon 
discharge for all patients leaving Siyaphila regardless of whether ART was initiated 
or not. All patients commenced on ART, had follow up appointments at the outpatient 
ART clinic after two weeks. Thereafter they were seen at four and eight weeks of 
follow up. The good clinical response (92 % of the 64 patients followed up at 24 
weeks had virological suppression <400 copies/ml) from such an expedited 
programme of ART initiation has made such an intensive programme worthwhile. 
 Outcomes of the Siyaphila programme 
 The prevalence of the various opportunistic infections in this study is representative 
of what can be expected in most of the country. The distribution of baseline CD4 
counts in this population (three quarters of the patients below 50 cells/uL) differs 
















wards are generally sicker than patients seen in the clinics. They are sick enough to 
require admission for acute care of life threatening clinical conditions. The Siyaphila 
programme offers a critical additional entrance point into care for typically non-
ambulatory patients with advanced disease who have been shown under routine 
conditions to have low ART uptake after discharge. 17   Late presentation is likely to 
have arisen for various reasons including poor health care access, late HIV testing 
and, in some patients, the impact of denial and/or stigma. It is encouraging that 
mortality at 24 weeks after ART was 20 % only. The majority of those very ill patients 
survived and was doing well at six months.  
Twenty six percent (93 /358) of the patients in the study group that were evaluated 
for transfer to Siyaphila center for immediate ART were found to be eligible to start 
ART as inpatients. This evaluation was done based on biomedical and psychosocial 
criteria for ART readiness. These patients started treatment on ART after treatment 
for the HIV linked condition within a median of fifteen days from date of initial ward 
admission. This time falls within the time lines set by the national guidelines for 
expedited ART initiation.7 
Benefits of the programme to common infections in SA 
Tuberculosis is the commonest co-infection in HIV positive patients and comprises 
approximately sixty percent of all admissions. The use of the Siyaphila facility helped 
to provide isolation for cases of open TB as they posed a major challenge to 
infection control in the medical wards.  The other OIs were cryptococcal meningitis, 














Among the 93 (26 %) patients initiated on ART at Siyaphila five died during the in-
patient stay and 14 died after discharge. Only one patient with IRIS died during 
follow up post discharge, having been treated for cryptococcal meningitis.  IRIS was 
diagnosed in 8 %. These results demonstrate that the mortality due to IRIS is low in 
this setting and would not preclude any patient from qualifying for expedited ART 
initiation and being discharged for follow up. 
The mortality has been reduced now that ART is commenced soon after treatment 
of cryptococcal meningitis. 30 The greatest challenge in treating patients with ART
after the management of cryptococcal meningitis is the management of IRIS
cryptococcal disease which can be life threatening. However studies from the United
States of America suggest that an equal or greater risk exists in patients in whom
ART is delayed. 31 The prolonged stay in of these patients in the wards affords an
opportunity for monitoring adverse events of treatment. Patients can also be
counseled on ART readiness, and ART could be commenced before discharge from
the wards.
Univariate analysis of risk factors for poor outcome
In the univariate analysis, male gender had a threefold increased risk of death by 24 
weeks compared to females (p-0.03). The possible reason for this is seen 
anecdotally in the medical wards because of the late presentation of males to the 
hospital for care. This poor health seeking behaviour of males needs to be 
addressed. A difference in baseline CD4 cell count by gender was explored. There 
was no difference in baseline CD4 cell count (median baseline CD4 cell count 
















analysis of variance showed a p value = 0.49 which was statistically significant for 
comparison of mean CD4 cell count by gender. 
The non ART cohort 
The patients that were not initiated on ART before discharge are not included in this 
analysis. These patients received standard care under current guidelines. They were 
treated for the HIV–linked condition for which they were admitted. ART readiness 
training was provided for them and eligible patients were discharged to ART sites in 
the area of their residence. They are among patients for whom the cost of in-patient 
care at Siyaphila would have been prohibitive. Siyaphila is a state subsidised 
hospital and patients pay higher fees than that paid at fully owned state hospitals. 
These patients were discharged to government ART clinics where they would be 
able to access lifelong care.  Some patients died soon after admission due to 
terminal medical conditions as they presented in an advanced stage of illness. All 
these patients received good pain and symptom management according to standard 
palliative care guidelines. They were referred to home based care organizations that 
provide adequate pain management and appropriate symptom control as long as the 
patients require. 
Limitations of the study 
The limitation of this study lies in the lack of follow up data on patients in this study 
who did not initiate ART at Siyaphila. A pilot study was done at McCord hospital 
during the same period of this study .17 these patients did not enter the Siyaphila 
















months. This programme attempted to address this challenge by the expedited ART 
programme.  
Concluding remarks 
The programme to start ART as soon as possible after a patient is admitted to the 
hospital is not the most popular method of ART initiation. However the potential to 
reduce the high mortality among this patient population is clearly demonstrated by 
this study. This programme catered for those patients with the most advanced 
disease. The cost of inpatient care at Siyaphila is considerably lower than the daily 
costs in an acute care medical ward. From a cost point of view, the challenge is to 
establish a similar programme that can be scaled up. This must be balanced with the 
high costs to families and the health care system.32 the linkages to outpatient primary 
care follow up was very effective. As the clinic is based on the hospital campus most 
patients and their families are made familiar with the procedure of enrolment and 
follow up in the clinic before discharge. The electronic patient record system in the 
hospital and clinic facilitates this linkage of care .Only those patients that are bed 
bound upon discharge are referred to home based care networks in the area of their 
residence. This programme must involve disease specific treatment together with 
optimal pain and symptom control. It makes it possible to help bed-ridden patients 
who otherwise may not be able to access an outpatient programme. With this 
understanding, we predict based on our experience at Siyaphila that high uptake of 
ART can be achieved. Effort and resources should be spent to include such patients 
into inpatient treatment programmes such as this. This study provides evidence that 
















            CONCLUSIONS AND RECOMMENDATIONS  
It is acknowledged that the conclusions in this study were not derived from data in 
this study. These data are summarised from a review of the latest literature .These 
findings were proven in some randomised controlled trials already published. The 
study at Siyaphila has operationalised the findings of these randomised controlled 
trials and demonstrated good mortality outcomes at six months. This was done in the 
context of an inpatient programme .The Siyaphila model has demonstrated that  HIV 
care  and palliative care can be integrated to operationalise an expedited ART 
programme for the sickest patients. 
The objectives of the study outlined in the study protocol were achieved and 
described in the results section. Different opportunistic infections require different 
protocols of treatment as seen in previous reports. Recommendations for ART 
initiation in a sub acute ward of district hospitals will be made based on evidence in 
the literature from trials already published. And the best practice guidelines 
described in the Siyaphila programme.It must be noted however that the Siyaphila 
programme started before the results of the randomized trials were published. The 
protocols used were based on expert advice and current literature or guidelines as 
described in the literature search. 
The value of an interdisciplinary team in the wards 
The 24 week mortality in the programme was 20 % and was due to the effective role 














optimal service for patients are the unique needs that each patient brings to the
therapeutic encounter and the need for individualised attention. These unique needs 
include multiple opportunistic infections, psychosocial co morbidities, severe poverty, 
and alternative belief systems which may call into question the efficacy of allopathic 
medicines. With this understanding, we predict based on our experience at Siyaphila
that high uptake of ART can be achieved. At Siyaphila this has required the use of
staff with intimate knowledge of the patient population and an ability to communicate
effectively which included counsellors, spiritual care givers and psychologists as 
formal components of the care team. The multidisciplinary health team was a key
component to the success of the programme providing crucial support required for 
the ART preparation and training of extremely ill patients.
The use of a sub acute care ward for fast tracking ART initiation
The use of a sub acute care ward linked to the acute care wards for patients with
advanced HIV allowed us to provide a very high level of care for a portion of the
population. Their needs have not been met by the ART roll-out as it currently exists 
at a reasonable cost. Though innovative this programme has provided ART in a way
consistent with the aims articulated by the HIV AIDS National Strategic Plan for 
South Africa.
Care of patients who did not access ART 
The interdisciplinary team provides care for patients in the non-ART cohort. These 
















offered optimal treatment for symptoms and bereavement support for patients and 
families. Care was individualized for all patients depending on the clinical needs.  
Recommendations 
Protocols for sub acute care in patients with advanced HIV disease are made based 
on findings from this study. Experts at McCord Hospital were involved in designing 
recommendations for early ART initiation after diagnosis of opportunistic infections. 
This study provides crucial pilot data that can combine existing best practice reports 
and recommendations by the South African HIV Clinicians Society. These based 
recommendations can lead to broader discussions for the development of an in-
hospital based model of care for advanced HIV infection. 
 Based on evidence and best practice, the following guidelines are suggested for 
when to initiate ART after diagnosis of an acute opportunistic infection. 
a) Pulmonary and extra pulmonary tuberculosis: Begin ART once the patient has 
demonstrated no early adverse effect of tuberculosis therapy as early as one 
week after TB treatment initiation.  
b) Cryptococcal meningitis: Amphotericin B is recommended for at least 14 days 
with monitoring for renal dysfunction and hematological toxicity (anaemia) 
prior to initiation of ART. 
c) Pneumocystis pneumonia: After a week of acute treatment, which generally 
will include corticosteroids and high dose cotrimoxazole, ART is 
recommended as early as one week after PCP therapy initiated. 
d) For all other AIDS associated opportunistic infections and associated 
















e) For conditions for which there is no effective disease directed therapy, 
consider starting ART earlier viz. Microsporidosis, Cryptosporidiosis, Kaposi’s 
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 WHO STAGING OF HIV/AIDS 
WHO Stage 1 
Seroconversion illness/asymptomatic infection 
Persistent generalized lymphadenopathy 
Performance status 1(fully active and asymptomatic) 
WHO Stage 2
Less than 10%weight loss
Herpes zoster
Minor mucocutaneous manifestations
Recurrent upper respiratory tract infections
Performance status 2(symptomatic but near fully active)
WHO Stage 3 
More than 10%weight loss 
Chronic diarrhoea for >one month 
Prolonged fever 
Oral candida, chronic vaginal candidiasis/ Oral hairy leukoplakia 
Severe bacterial infections 
Pulmonary tuberculosis (TB) 
















WHO Stage 4(AIDS) 
Extrapulmonary TB 
Pneumocystis carinii pneumonia 
Cryptococcal meningitis 






HIV wasting syndrome 
HIV encephalopathy 
Kaposis’s sarcoma (KS) 
Progressive multifocal leukoencephalopathy (PML) 
Disseminated mycosis 
Atypical mycobacteriosis 
Non-typhoid Salmonella bacteraemia 
Lymphoma 
Recurrent pneumonia 
Invasive cervical carcinoma 



















                                              APPENDIX   2 
                    PATIENT DATA COLLECTION FORM: INITIAL FORM 
 
Date form completed:  --------------/-------------/-------------- 
                                                      Day          Month       Year 
Study ID number:  ---------------------------- 
Date of ward admission:  -------------/------------/------------- 
                                                       Day        Month        Year 
Date of birth:      ------------/------------/------------ 
                              Day        Month        Year 
Gender:              Female               Male 
Ethnic group:       Black                  White             Indian            Coloured 
What was the final diagnosis? 
    Medical problems / Opportunistic infections  
1. Pulmonary Tb (see below)                  11.    T gondii 
2. Tb meningitis   (see below)                 12.    Kaposi’s sarcoma 
3. Extra pulmonary Tb (not TBM)            13.    CMV of any organ  
4. PCP                    14.    HIV associated dementia 
5. Cryptococcus meningitis                      15.    HIV wasting 
6. Diarrhoea > 14 days                            16.    Mycobacterium avium 
7. Herpes Zoster                                      17.    Recurrent pneumonia 
8. Esophageal candidiasis                       18.    Cardiac failure 
9. Diabetes                                               19.    Renal failure 
10.  Hypertension                                       20.    Liver disease-cause 
                                                                         21.    Other (specify----------------------- 
 
Clinical exam: 

















Baseline blood test 
Latest CD4 count _________________________ Date:  -----------/-----------/----------- 
               
 Latest Viral load   ________________________   Date:   ----------/-----------/------------- 
                                        
     Latest FBC/Hb   __________________________   Date:  --------------/--------------/------
----- 
     Latest albumin_______________                            Date: -------------/-------------/---------
--  
                                   
     Treatment: 
Treatment given for OI: -----------------------------                 Date: --------------/------------/--
---------- 
                                Day          Month        Year 





























Date of admission to Siyaphila:  -----------------/-----------------/---------------- 
  Day     Month  Year 
Date of commencement of ARVS: ---------------/---------------/------------------ 
      Day      Month   Year 
ARV regimen:   ---------------------------------------- 






Date of discharge from Siyaphila: --------------------/------------------/-----------------
 Day   Month     Year 



















    APPENDIX  3 
      PATIENT DATA COLLECTION FORM: FOLLOW –UP VISITS 
Study ID number: --------------------------- 
Date    ---------------/------------------/-------------Completed by ____________________ 
  Day  Month    Year 
Clinical exam: 
Current Weight: -------------------kg Date: -------------/-------------/------------
Day  Month     Year 
Did the patient experience any of the ffg or get admitted to the hospital since the last 
visit? What were the dates?
Medical problems / Opportunistic infections 
1. Pulmonary Tb (see below) 11. T gondii
2. Tb meningitis   (see below) 12. Kaposi’s sarcoma
3. Extra pulmonary Tb (not TBM) 13. CMV of any organ other than
4. PCP 14. HIV associated dementia
5. Cryptococcal meningitis   15. HIV wasting
6. Diarrhoea > 14 days 16. Mycobacterium avium
7. Herpes Zoster    17. Recurrent pneumonia
8. Esophageal candidiasis 18. Cardiac failure
9. Diabetes 19. Renal failure














Did the patient have any of the ffg adverse events after ARVs? 
Is the patient not in the clinic for one of the ffg reasons
     Cause Date 
Lost to follow up 
Changed to service provider 
Death 
Stopped taking medicines 
Other 
Adverse event Date 
Peripheral neuropathy 
Anaemia 
Lactic acidosis /Hyperlactatemia 
Rash 
Drug induced liver injury 
Neuropsych symptoms 
IRIS – TB 
IRIS – CRYPTO 
IRIS – PCP 

















Latest CD4 count_____________ Date------------/------------/------------------ 
Day        Month        Year 
Latest Viral Load-_____________Date------------/------------/------------------- 
Day           Month       Year 
Latest FBC ____/Hb__________ Date-----------/--------------/------------------- 
       Day           Month          Year 
Latest ALB_________________Date-------------/--------------/------------------- 
       Day              Month             Year 
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